DiaMedica announces last patient out for Phase II diabetes trial

The study will evaluate DM-83s effectiveness at controlling blood sugar levels in type 2 diabetics after consuming a meal. The 20 patient trial will measure both changes in insulin and glucose as the study’s primary endpoints with final results to be analyzed and released by early third quarter, 2008.

Rick Pauls, president and CEO of DiaMedica, said: “Patients will compare the effects of DM-83 to a placebo in this cross over study. In this regard, each individual will serve as their own control and therefore we will have a better idea as to how well DM-83 is able to manage a type 2 diabetic’s blood sugar and insulin levels in the post prandial state.”